Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation

Liver Transplantation

Volumn 20, Issue 8, 2014, Pages 912-921

  Chok, Kenneth S H ^a   Cheung, Tan To ^a   Lo, Regina C L ^a,b   Chu, Ferdinand S K ^a   Tsang, Simon H Y ^a   Chan, Albert C Y ^a   Sharr, William W ^a   Fung, James Y Y ^a,b   Dai, Wing Chiu ^a   Chan, See Ching ^a,b   Fan, Sheung Tat ^a,b   Lo, Chung Mau ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CISPLATIN; GELFOAM; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER RECURRENCE; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPARATIVE STUDY; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH INTENSITY FOCUSED ULTRASOUND DEVICE; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MODEL FOR END STAGE LIVER DISEASE SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TRANSARTERIAL CHEMOEMBOLIZATION; TUMOR NECROSIS; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; ECHOGRAPHY; END STAGE LIVER DISEASE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84904962298     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23892     Document Type: Article

References (27)

1. El-Serag HB, Mason AC,. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
2. Hospital Authority. Hong Kong Cancer Registry. http://www3.ha.org.hk/ cancereg. Accessed April 2014.
3. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J,. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322-330.
4. Fong Y, Sun RL, Jarnagin W, Blumgart LH,. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229: 790-799.
5. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
6. Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F, Verslype C,. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis 2009; 27: 157-163.
7. Kennedy JE,. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer 2005; 5: 321-327.
8. Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, et al. Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 2005; 235: 659-667.
9. Wu F, Wang ZB, Chen WZ, Zhu H, Bai J, Zou JZ, et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol 2004; 11: 1061-1069.
10. Wu F, Wang ZB, Chen WZ, Wang W, Gui Y, Zhang M, et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of 1038 patients with solid carcinomas in China: an overview. Ultrason Sonochem 2004; 11: 149-154.
11. Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, et al. Extracorporeal focused ultrasound surgery for treatment of human solid carcinomas: early Chinese clinical experience. Ultrasound Med Biol 2004; 30: 245-260.
12. Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, et al. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg 2011; 253: 981-987.
13. Cheung TT, Chu FS, Jenkins CR, Tsang DS, Chok KS, Chan AC, et al. Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma. World J Surg 2012; 36: 2420-2427.
14. Cheung TT, Chok KS, Lo RC, Sharr WW, Chan SC, Poon RT, et al. High-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients awaiting liver transplantation. Hepatobiliary Pancreat Dis Int 2012; 11: 542-544.
15. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.; for EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
17. Organ Procurement and Transplantation Network. Allocation of livers. 3.6.4.4. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/ policy-8.pdf. Accessed April 2014.
18. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al.; for Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
20. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
21. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al.; for Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002 359: 1734-1739.
22. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using Organ Procurement Transplant Network data. Liver Transpl 2009; 15: 859-868.
23. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
24. Cescon M, Cucchetti A, Ravaioli M, Pinna AD,. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013; 58: 609-618.
25. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12: 665-673.
26. Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415-423.
27. Chok KS, Ng KK, Poon RT, Lam CM, Yuen J, Tso WK, Fan ST,. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 2006; 141: 1231-1236.